Immucor, Inc.

Galileo cleared by U.S. Food and Drug Administration for use in U.S.

Published in MD Week, May 28th, 2004

Immucor, Inc., (BLUD), a provider of automated instrument-reagent systems to the blood transfusion industry, announced that the U.S. Food and Drug Administration has cleared Galileo for marketing in the United States.

Galileo is Immucor's second-generation, bidirectional, fully automated, walk-away instrument for the hospital blood bank transfusion laboratory, donor centers, and reference laboratories.

Commenting on this clearance, Edward L. Gallup, chairman and CEO, stated, "This is a major milestone in the history of Immucor. Galileo offers our customers significant labor reduction while increasing productivity and patient safety. There are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of MD Week

Source: MD Week (2004-05-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry